Skip to main content

Table 1 Details of the data presented by the included studies

From: Immunogenicity of COVID-19 mRNA vaccines in immunocompromised patients: a systematic review and meta-analysis

Study (first author)

Country

Study design

Total sample size

Case

Control

Etiology of IC condition

Type of vaccine

No. of cases

Male, % of cases

Age

No. of non-cases (if applicable)

Male, % of non-cases

Age

Sattler A

Germany

Prospective cohort

78

39

71.8

57.3

39

51.2

53.0

Transplant

BNT162b2 (Pfizer/BionTech)

Rincon-Arevalo H

Germany

Prospective cohort

75

40

70

62.4 [51.2–69.5]*

35

57.1

51 [34–80]*

Transplant

BNT162b2 (Pfizer/BionTech)

Korth J

Germany

Prospective cohort

46

23

48

57.7

23

39

44.4

Transplant

BNT162b2 (Pfizer/BionTech)

Rabinowich L

Israel

Cross-sectional

105

80

70

60.1

25

32

52.7

Transplant

BNT162b2 (Pfizer/BionTech)

Schramm R

Germany

Prospective cohort

100

50

64

55

50

34

47

Transplant

BNT162b2 (Pfizer/BionTech)

Cao J

USA

Retrospective cohort

47

37

72.9

64 [50–69]*

10

20

66 [57–75]*

Transplant

mRNA-1273 (Moderna) or BNT162b2 (Pfizer/BionTech)

Grupper A

Israel

Retrospective cohort

151

136

81.7

58.6

25

32

52.7

Transplant

BNT162b2 (Pfizer/BionTech)

Marinaki S

Greece

Prospective cohort

150

34

79.4

60 [49.1–68.4]*

116

–

–

Transplant

BNT162b2 (Pfizer/BionTech)

Rashidi-Alavijeh J

Germany

Prospective cohort

63

43

60.5

57 [49–64]*

20

45

43.5 [38–53.5]*

Transplant

BNT162b2 (Pfizer/BionTech)

Hod T

Israel

Prospective cohort

322

120

80

59.7

141

30.2

57.04

Transplant

BNT162b2 (Pfizer/BionTech)

Stumpf J

Germany

Prospective cohort

512

368

65.5

57.3

144

23.6

48

Transplant

(a) mRNA-1273 (Moderna) (n = 143);

(b) BNT162b2 (Pfizer/BionTech) (n = 369)

Firket L

USA

Retrospective cohort

40

20

45

51.2

20

65

48.3

Transplant

BNT162b2 (Pfizer/BionTech)

Peled Y

Israel

Prospective cohort

213

77

64

62 [49–68]*

136

37

63

Transplant

BNT162b2 (Pfizer/BionTech)

Monin L

UK

Prospective cohort

205

151

52

73 [64.5–79.5]*

54

52

40.5 [31.3–50]*

Malignancy

BNT162b2 (Pfizer/BionTech)

Pimpinelli F

Italy

Prospective cohort

128

92

53/2

70*

36

0

81

Malignancy

BNT162b2 (Pfizer/BionTech)

Massarweh A

Israel

Prospective cohort

180

102

57

66 [56–72]*

78

32

62 [49–70]*

Malignancy

BNT162b2 (Pfizer/BionTech)

Agbarya A

Israel

Cross-sectional

355

140

54

65.3

215

37.2

62.5

Malignancy

BNT162b2 (Pfizer/BionTech)

Herishanu Y

Israel

Prospective cohort

219

167

67.1

71 [63–76]*

52

–

69 [63–73.7]*

Malignancy

BNT162b2 (Pfizer/BionTech)

Iacono D

Italy

Cross-sectional

108

36

41.6

82*

72

–

 ≥ 66

Malignancy

BNT162b2 (Pfizer/BionTech)

Malard F

France

Retrospective cohort

225

195

60

68.9*

30

–

–

Malignancy

BNT162b2 (Pfizer/BionTech)

Eliakim-Raz N

Israel

Prospective cohort

161

95

58

65 [56–72]*

66

32

62 [50–70]*

Malignancy

BNT162b2 (Pfizer/BionTech)

Herzog Tzarfati K

Israel

Prospective cohort

423

315

56

71 [61–78]*

108

44

69 [58–74]*

Malignancy

BNT162b2 (Pfizer/BionTech)

Reuken P

Germany

Prospective cohort

55

28

46.4

42 [36–59]*

27

–

–

Autoimmune

BNT162b2 (Pfizer/BionTech)

Geisen UM

Germany

Retrospective cohort

68

42

35.7

50.5

26

30.8

37.5

Autoimmune

mRNA-1273 (Moderna) or BNT162b2 (Pfizer/BionTech)

Furer V

Israel

Prospective cohort

807

686

30.7

59 [19–88]*

121

35

50*

Autoimmune

BNT162b2 (Pfizer/BionTech)

Prendecki M

UK

Prospective cohort

155

85

52.1

52 [39.9–63.9]*

70

–

41.4*

Autoimmune

BNT162b2 (Pfizer/BionTech)

  1. *Median [IQR] is reported; otherwise the mean is reported